Hajer Lejri-El Euchi1, Emmanuel Chirpaz2, Aurélie Foucher3, Nathalie Sultan-Bichat4, Andry Randrianjohany5, Patrice Poubeau6, Etienne Gamon7, Céline Roussin8, Sophie Osdoit9, Loïc Raffray10. 1. Internal Medicine and Dermatology Unit, Reunion University Hospital, Saint Denis, Reunion Island, France. Electronic address: hajer.eleuchi@gmail.com. 2. Statistics and methodological Unit, INSERM CIC 1410, Reunion University Hospital, Saint Denis, Reunion Island, France. Electronic address: emmanuel.chirpaz@chu-reunion.fr. 3. Internal Medicine Unit, Reunion University Hospital, Saint Pierre, Reunion Island, France. Electronic address: aurelie.foucher@chu-reunion.fr. 4. Internal Medicine and Dermatology Unit, Gabriel Martin Hospital, Saint Paul, Reunion Island, France. Electronic address: sultanbichat.n@ch-gmartin.fr. 5. Internal Medicine Unit, GHER Hospital, Saint Benoit, Reunion Island, France. Electronic address: a.randrianjohany@gher.fr. 6. Internal Medicine Unit, Reunion University Hospital, Saint Pierre, Reunion Island, France. Electronic address: patrice.poubeau@chu-reunion.fr. 7. Rheumatology Unit, Reunion University Hospital, Saint Denis, Reunion Island, France. 8. Internal Medicine and Dermatology Unit, Gabriel Martin Hospital, Saint Paul, Reunion Island, France. Electronic address: roussin.c@ch-gmartin.fr. 9. Internal Medicine and Dermatology Unit, Reunion University Hospital, Saint Denis, Reunion Island, France. Electronic address: sophie.osdoit@chu-reunion.fr. 10. Internal Medicine and Dermatology Unit, Reunion University Hospital, Saint Denis, Reunion Island, France. Electronic address: loic.raffray@chu-reunion.fr.
Abstract
BACKGROUND: Patients under biological therapy for auto-immune disease are considered immunosuppressed and several recent recommendations highlight the need for vaccination against influenza and pneumococcal infections. The aims of this study were to evaluate influenza and pneumococcal vaccine coverage among patients receiving biological therapy and identify factors associated with vaccine uptake within this population. METHODS: A retrospective cross-sectional study was performed in adult patients attending hospitals for an auto-immune/inflammatory disease and treated with biological therapy. Vaccine uptake was evidenced from patient's medical records or from their pharmacist's records. Questionnaires about attitudes and knowledge regarding vaccinations were administered to patients and their physicians. Multivariable logistic regression was used to determine factors significantly associated with influenza and pneumococcal vaccine receipt. RESULTS: A total of 208 patients were included: 52% female and mean age 50.6 (± 14.7) years. Among them 173 completed the questionnaire while 72 physicians replied. Underlying inflammatory diseases were rheumatisms (46%), bowel diseases (31%) and skin diseases (23%). Vaccine uptake was 28% for influenza, 48% for pneumococcus and 22% received both vaccines. Main factors associated to positive uptake were receiving a prescription from a physician, as well as having a good knowledge of vaccines. Factors limiting vaccination were a negative attitude toward vaccines in general, and belonging to the group of inflammatory bowel diseases. CONCLUSIONS: Vaccine coverage for influenza and pneumococcal infections are low in the patients under biologics for auto-immune/inflammatory disease. Health policies should reinforce information and promotion of these vaccines among these patients but also the prescribers.
BACKGROUND:Patients under biological therapy for auto-immune disease are considered immunosuppressed and several recent recommendations highlight the need for vaccination against influenza and pneumococcal infections. The aims of this study were to evaluate influenza and pneumococcal vaccine coverage among patients receiving biological therapy and identify factors associated with vaccine uptake within this population. METHODS: A retrospective cross-sectional study was performed in adult patients attending hospitals for an auto-immune/inflammatory disease and treated with biological therapy. Vaccine uptake was evidenced from patient's medical records or from their pharmacist's records. Questionnaires about attitudes and knowledge regarding vaccinations were administered to patients and their physicians. Multivariable logistic regression was used to determine factors significantly associated with influenza and pneumococcal vaccine receipt. RESULTS: A total of 208 patients were included: 52% female and mean age 50.6 (± 14.7) years. Among them 173 completed the questionnaire while 72 physicians replied. Underlying inflammatory diseases were rheumatisms (46%), bowel diseases (31%) and skin diseases (23%). Vaccine uptake was 28% for influenza, 48% for pneumococcus and 22% received both vaccines. Main factors associated to positive uptake were receiving a prescription from a physician, as well as having a good knowledge of vaccines. Factors limiting vaccination were a negative attitude toward vaccines in general, and belonging to the group of inflammatory bowel diseases. CONCLUSIONS: Vaccine coverage for influenza and pneumococcal infections are low in the patients under biologics for auto-immune/inflammatory disease. Health policies should reinforce information and promotion of these vaccines among these patients but also the prescribers.
Authors: Laura Boekel; Femke Hooijberg; Yaëlle R Besten; Erik H Vogelzang; Maurice Steenhuis; Maureen Leeuw; Sadaf Atiqi; Ronald van Vollenhoven; Willem F Lems; Wouter H Bos; Carla A Wijbrandts; Martijn Gerritsen; Charlotte Krieckaert; Alexandre E Voskuyl; Irene E van der Horst-Bruinsma; Sander W Tas; Maarten Boers; Theo Rispens; Michael T Nurmohamed; Gertjan Wolbink Journal: Lancet Rheumatol Date: 2022-02-08
Authors: Gabriel Figueroa-Parra; Jorge Antonio Esquivel-Valerio; Leticia Santoyo-Fexas; Andrea Moreno-Salinas; Carmen Magdalena Gamboa-Alonso; Ana Laura De Leon-Ibarra; Dionicio Angel Galarza-Delgado Journal: Hum Vaccin Immunother Date: 2020-09-29 Impact factor: 3.452